Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.1.4.35: 3',5'-cyclic-GMP phosphodiesterase

This is an abbreviated version!
For detailed information about 3',5'-cyclic-GMP phosphodiesterase, go to the full flat file.

Word Map on EC 3.1.4.35

Reaction

guanosine 3',5'-cyclic phosphate
+
H2O
=
GMP

Synonyms

3',5'-cyclic GMP phosphodiesterase, 3',5'-cyclic guanosine monophosphate-specific phosphodiesterase, 3',5'-cyclic nucleotide phosphodiesterase 5, cd-PDE5, cG-PDE, cGMP 3',5'-cyclic phosphodiesterase subunit delta, cGMP binding phosphodiesterase, cGMP phosphodiesterase, cGMP phosphodiesterase 5, cGMP phosphodiesterase 6, cGMP phosphodiesterase 6alpha' subunit, cGMP phosphodiesterase6, cGMP-binding cGMP specific phosphodiesterase, cGMP-binding cGMP-specific PDE, cGMP-binding cGMP-specific phosphodiesterase, cGMP-PDE, cGMP-phosphodiesterase, cGMP-phosphodiesterase-5, cGMP-selective phosphodiesterase, cGMP-specific cGMP-binding phosphodiesterase, cGMP-specific PDE, cGMP-specific PDE5, cGMP-specific PDE5A1, cGMP-specific phosphodiesterase, cGMP-specific phosphodiesterase 5, cGMP-specific phosphodiesterase type 9, cGMP-specific phosphodiesterase-5, cGMP-stimulated phosphodiesterase, cyclic 3',5'-GMP phosphodiesterase, cyclic GMP hydrolyzing phosphodiesterase 5, cyclic GMP phosphodiesterase, cyclic GMP-phosphodiesterase, cyclic guanosine 3',5'-monophosphate phosphodiesterase, cyclic guanosine 3',5'-phosphate phosphodiesterase, cyclic guanosine monophosphate phosphodiesterase, cyclic guanosine monophosphate-specific phosphodiesterase 5, cyclic-GMP phosphodiesterase, DdPDE3, DmPDE6, Drosophila PDE6-like enzyme, GbpA, gigh-affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, GMP-PDE, guanosine 3',5'-cyclicmonophosphate-specific PDE, guanosine cyclic 3',5'-phosphate phosphodiesterase, PDB5, PDE, PDE-5, PDE-6, PDE4, PDE5, PDE5/6, PDE5/PDE6cd, PDE5A, PDE5A1, PDE6, PDE6AB, PDE6alpha, PDE6alpha', PDE6B, PDE6beta, PDE6C, PDE6D, PDE6gamma, PDE6R, PDE9, PDE9A, PDE9A1, PdeD, PDEdelta, PDEgamma, PfPDE1, phospho-diesterase-5, phosphodiesterase, phosphodiesterase 5, phosphodiesterase 5 (cGMP-specific), phosphodiesterase 6C, phosphodiesterase 9, phosphodiesterase cGMP, phosphodiesterase isoenzyme 5, phosphodiesterase subtype 5, phosphodiesterase type 5, phosphodiesterase type-5, phosphodiesterase, guanosine cyclic 3',5'-phosphate, phosphodiesterase-5, phosphodiesterase-6, PrBP/delta, suPDE5, type 5 phosphodiesterase, type 9 cGMP-specific phosphodiesterase, type-5 phosphodiesterase, xGMP-specific PDE

ECTree

     3 Hydrolases
         3.1 Acting on ester bonds
             3.1.4 Phosphoric-diester hydrolases
                3.1.4.35 3',5'-cyclic-GMP phosphodiesterase

Inhibitors

Inhibitors on EC 3.1.4.35 - 3',5'-cyclic-GMP phosphodiesterase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
IC50: 0.0121 mM, PDE5
(1R,3S)-2-acetyl-1-(2H-1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-b-carboline-3-carboxylate
ZINC03024617
(1S,3R)-2-acetyl-1-(2H-1,3-benzodioxol-5-yl)-2,3,4,9-tetrahydro-1H-b-carboline-3-carboxylate
ZINC03024615
(1S,3S,4aS,9aR)-1-(2H-1,3-benzodioxol-5-yl)-2-(chloroacetyl)-2,3,4,4a,9,9a-hexahydro-1H-b-carboline-3-carboperoxoic acid
ZINC21986065
(2R)-4-[(2H-1,3-benzodioxol-5-yl)methyl]-1-(3-methoxybenzoyl)-N-methylpiperazine-2-carboxamide
ZINC24891165
(2R)-N-[[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-4-(methylsulfanyl)butanamide
ZINC32995888
(2S)-N-[[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-4-(methylsulfanyl)butanamide
ZINC32995890
(2Z)-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one
-
IC50: 0.00067 mM, PDE5
(3R)-1-(2H-1,3-benzodioxole-5-carbonyl)-4-(2-methoxyphenyl)-N-[(pyridin-3-yl)methyl]pyrrolidine-3-carboxamide
ZINC36055139
(3S)-N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-2-(furan-2-carbonyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
ZINC23055991
(4-(4-[2-ethyl-phenylamino)-methylene]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl)-benzoic acid
-
0.00001 mM, 50% inhibition
(6R,12aR)-2-propyl-6-(3,4,5-trimethoxyphenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC02092043
(6R,12aR)-6-(2H-1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC12360812
(6R,12aR)-6-(4-ethoxy-3-methoxyphenyl)-2-(2-methylpropyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC15955458
(6R,12aS)-2-methyl-6-(3,4,5-trimethoxyphenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC16031243; ZINC16042566
(6R,12aS)-2-propyl-6-(3,4,5-trimethoxyphenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC11692256
(6R,12aS)-6-(4-ethoxy-3-methoxyphenyl)-2-(3-methylbutyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC02120502
(6S,12aR)-2-benzyl-6-(3,4-dimethoxyphenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC16043001
(6S,12aS)-2-methyl-6-(3,4,5-trimethoxyphenyl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC02093785
(6S,12aS)-2-[(furan-2-yl)methyl]-6-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC00490454
(6S,12aS)-2-[2-(3,4-dimethoxyphenyl)ethyl]-6-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC26772005
(6S,12aS)-6-(2H-1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ZINC08204637
(E)-1-(3-(cyclopentyloxy)-4-methoxyphenyl)ethanone O-carbamoyl oxime
-
filaminast
1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride
specific inhibitor of PDE5
1,2-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium
-
-
1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)pyrazol[3,4d]-pyrimidin-4-(5H)-one
-
0.000006 mM, 50% inhibition in sham operated rats
1-(2-chlorophenyl)-6-((2R)-3,3,3-trifluoro-2-methylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one
1-(2-ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
1-(2-ethoxyethyl)-3-methyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
1-(3-chloro-4-methoxybenzyl)-3-(cis-4-hydroxycyclohexyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-6-carbonitrile
-
-
1-benzyl-2-[4-[2-(2-phenyl-1H-benzimidazol-1-yl)ethoxy]phenyl]-1H-benzimidazole
-
-
1-benzyl-2-[4-[2-cyclohexyl-2-(2-phenyl-1H-benzimidazol-1-yl)ethoxy]phenyl]-1H-benzimidazole
-
-
1-[(3R)-1-(2H-1,3-benzodioxol-5-yl)-5-oxopyrrolidine-3-carbonyl]-N-(4-methoxyphenyl)-L-prolinamide
ZINC40146722
1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloroquinazolin-2-yl]piperidine-4-carboxylic acid
-
-
1-[9-[(3-chloro-4-methoxybenzyl)amino]-3-ethyl-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-yl]piperidin-4-ol
-
-
1-[9-[(3-chloro-4-methoxybenzyl)amino]-3-ethyl-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-yl]piperidine-4-carboxylic acid
-
-
1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate
trivial name sildenafil citrate or Viagra
2',3'-cGMP
-
-
2,2',2'',2'''-[(4,8-dipiperidin-1-ylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol
-
-
2-(2,4-dihydroxyphenyl)-8-[5-hydroxy-5-methyl-2-(1-methylethenyl)hexyl]-5-methoxy-4H-chromene-3,7-diol
-
-
2-(2-ethoxyphenyl)-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one
-
-
2-(2-methylpyridin-4-yl)methyl-4-(3,4,5-trimethoxyphenyl)-8-(pyrimidin-2-yl)methoxy-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride
-
i.e. T-0156, IC50: 0.23 mM, potent and highly selective phosphodiesterase type 5 inhibitor
2-(2-propoxyphenyl)-1,7-dihydro-6H-purin-6-one
-
-
2-(5-amino-2-propoxyphenyl)thieno[2,3-d]pyrimidin-4(3H)-one
-
-
2-(5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl)-5-methylquinazolin-4(3H)-one
-
-
2-bromo-5-ethyl-7,8-dihydro-1-[(4-hydroxyphenyl)methyl]-7(R)-(phenylmethyl)-1H-imidazo[2,1-b]purin-4(5H)-one
-
-
2-cyclohexyl-2-methyl-N1-[3-(2-oxo-1,2-dihydro-6-quinolyl,oxy)propyl]-1-hydrazinecarboxamide
-
IC50: 0.0027 mM, PDE5
2-methoxy-7-methyl-9-propylimidazo[1,5-a]pyrido[3,2-e]pyrazin-6(5H)-one
-
-
2-[1-(2,4-dichlorobenzyl)-2-methyl-5-(methylmercapto)-1H-indol-3-yl] ethanaminium chloride
-
IC50: 0.002 mM, PDE5
2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
trivial name vardenafil or Levitra
2-[2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl]-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one
-
vardenafil
3',5'-cAMP
3',5'-cIMP
-
-
3,7-dihydro-8-[(1-hydroxymethyl)-3-cyclopenten-1-yl]amino-7-[(4-methoxyphenyl)methyl]-1,3-dimethyl-1H-purine-2,6-dione
-
-
3-(4-ethylpiperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-(cyclopentylmethoxy)-N-(2,6-dichlorophenyl)-4-methoxybenzamide
-
piclamilast
3-(cyclopropylmethoxy)-N-(2,6-dichlorophenyl)-4-(difluoromethoxy)benzamide
-
roflumilast
3-([2-[(2-hydroxyethyl)amino]ethyl]amino)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-ethyl-5-(4-methyl-1,4-diazepan-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-(morpholin-4-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-(piperazin-1-yl)-1-(2-propoxyethyl)-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-(piperazin-1-yl)-1-[2-(propan-2-yloxy)ethyl]-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-5-[(3R)-3-methylpiperazin-1-yl]-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-N-(4-fluorophenyl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-ethyl-N5-(1-methylpiperidin-4-yl)-N7-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
-
-
3-isobutyl-1-methyl-8-methoxymethylxanthine
-
-
3-isobutyl-1-methylxanthine
3-methyl-5-[(3R)-3-methylpiperazin-1-yl]-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-methyl-5-[(3S)-3-methylpiperazin-1-yl]-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-methyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-methyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[(2-aminoethyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5-hydroxy-8-(1-hydroxy-2-methylprop-2-en-1-yl)-2-(4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl beta-D-glucopyranoside
-
-
3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-(2,2-dihydroxypropyl)-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-(2-hydroxyethyl)-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]-pyrazin-2(1H)-one
-
-
3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5
3-[4-(3-hydroxypropyl)-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-(3-hydroxypropyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-[(2R)-2-hydroxypropyl]-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-[(2R,3R)-3-hydroxybutan-2-yl]-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-[(2S)-2-hydroxypropyl]-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
3-[4-[(2S,3R)-3-hydroxybutan-2-yl]-1,4-diazepan-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
4-(1,3-benzodioxol-5-ylmethoxy)-2-(1H-imidazol-1-yl)-5-phenylpyrimidine
-
-
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
-
Ro20-1724
4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid
-
cilomilast
4-[3-ethyl-7-(pyrimidin-4-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperazin-2-one
-
-
4-[7-hydroxy-8-[5-hydroxy-5-methyl-2-(1-methylethenyl)hexyl]-5-methoxy-4H-chromen-2-yl]benzene-1,3-diol
-
-
5-(1,4-diazepan-1-yl)-3-ethyl-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
5-(1,4-diazepan-1-yl)-3-methyl-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
-
-
5-(2-propoxyphenyl)-2,3-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
-
-
5-(2-propoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
-
zardaverine
5-ethyl-7,8-dihydro-2,7(R)-bis(phenylmethyl)-1H-imidazo[2,1-b]purin-4(5H)-one
-
-
6-(3-(3-cyclooctyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone
-
IC50: 0.0025 mM, PDE5
6-benzo[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydropyrazinol[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
trivial name tadalafil or Cialis
6-deoxy-3-O-[6-deoxy-4-O-[7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-8-(2-methylprop-1-en-1-yl)-4-oxo-3,4-dihydro-2H-chromen-3-yl]-alpha-L-mannopyranosyl]-alpha-L-mannopyranose
-
-
7-(6-methoxypyridin-3-yl)-3-(piperazin-1-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one
-
-
8-(5-[[4-(2-hydroxyethyl)-1,4-diazepan-1-yl]sulfonyl]-2-propoxyphenyl)-6-propyl-6,6a,9,9a-tetrahydro-5H-[1,2,4]triazolo[3,4-i]purin-5-one
-
-
8-bromo-1-ethyl-3,7-dihydro-7-[(4-methoxyphenyl)methyl]-3-(2-methylpropyl)-1H-purine-2,6-dione
-
-
8-methoxymethyl-isobutylmethylxanthine
-
inhibits isoform PDE5, is 3times more potent in inhibiting PDE5 than PDE1
9-[(3-chloro-4-methoxybenzyl)amino]-3-ethyl-N-methyl-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6-carboxamide
-
-
amentoflavone
-
IC50: 0.0117 mM
amrinone
-
IC50: 0.2296 mM, PDE5
ATP
-
slight inhibition at 1 mM
avanafil
-
TA-1790, highly selective inhibitor of PDE5
BAY 60-7550
-
-
BAY 73-6691
-
specific PDE9A inhibitor
benzamidenafil
-
i.e. N-(3,4-dimethoxy benzyl)-2-[[(1R,S)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide, potent and specific inhibitor of PDE-5
bilobetin
-
IC50: 0.00152 mM
Ca2+
-
inhibitory at 1 mM together with Mg2+ below 0.1 mM
Caffeine
cAMP
-
inhibition at high concentrations
carboxyamidotriazole
cGMP
-
inhibition above 0.001 mM
chamomile
-
weak, but still statistically significant inhibition of PDE5A1
Cilostamide
cilostazol
-
IC50: 0.0044 mM, PDE5
Colchicine
-
-
cone Pgamma subunit
-
PDE6C is potently inhibited by the recombinant cone and rod Pgamma-subunits with slight selectivity for the cone Pgamma
-
CP461
-
-
delphinidin
-
-
delphinidin 3-glucoside
-
-
deltarasin
-
-
deltazinone 1
-
-
dibutyryl 3',5'-cAMP
-
-
dioclein
-
dioclein is at least 11times more potent in inhibiting calmodulin-activated PDE1 than other PDE types. Among PDE1-PDE5, dioclein is at least 11fold more selective for the activated PDE1 isoform compared to PDE5 (16fold)
diosmetin
-
IC50: 0.015 mM, PDB5
dipyridamole
E4021
Evo48
-
potent inhibitor of PDE5
-
exisulind
-
-
fructose 1,6-bisphosphate
-
-
fructose 6-phosphate
-
-
genistein
-
IC50: 0.073 mM, PDB5
ginkgetin
-
IC50: 0.00059 mM
GTP
-
slight inhibition at 1 mM
histone
-
-
Inhibitor protein
-
inhibitory gamma subunit of PDE
-
i.e. Pgamma
-
luteolin
-
IC50: 0.0193 mM, PDB5
malvidin
-
IC50: 0.0354 mM
malvidin-3-O-beta-glucoside
-
IC50: 0.0116 mM
methyl 2-[(3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-carboxylate
ZINC29158966
Mg2+
-
inhibitory below 0.1 mM together with Ca2+ at 1 mM
Milrinone
-
IC50: 0.0491 mM, PDE5
MY-5445
-
inhibition significantly increases contractility in hypertrophied myocardium
N-(3-chloro-4-methoxybenzyl)-2-pyridin-4-yl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-amine
-
-
N-(3-chloro-4-methoxybenzyl)-3-ethyl-6-(pyridin-4-ylmethyl)-3H-pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-9-amine
-
-
N-[(1S)-1-[1-(2H-1,3-benzodioxole-5-carbonyl)piperidin-4-yl]-2-oxo-2-(pyrrolidin-1-yl)ethyl]-2-methylbenzamide
ZINC36210867
N-[(S)-[(3R)-1-(2H-1,3-benzodioxole-5-carbonyl)piperidin-3-yl](pyridin-2-yl)methyl]acetamide
ZINC19020327
N-[3-(1,3-dimethyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-propoxyphenyl]methanesulfonamide
-
-
N-[3-(4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]piperidine-1-carboxamide
-
-
N-[3-(4-oxo-3,4-dihydro[1]benzofuro[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]morpholine-4-carboxamide
-
-
N-[[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-4-(2,5-dioxopyrrolidin-1-yl)-N-methylbenzamide
ZINC23183710
N5-(2-aminoethyl)-3-ethyl-N7-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
-
-
papaverine
-
-
Pb2+
-
-
peonidin
-
-
peonidin 3-glucoside
-
-
petunidin
-
-
petunidin 3-glucoside
-
-
PF-3717842
high-affinity phosphodiesterase-5 inhibitor
Pgamma-inhibitory peptide
-
-
-
Pgamma-inhibitory peptide Pgamma63-87
-
-
-
Pgamma-inhibitory peptide Pgamma70-87
-
-
-
PgammaPDE6
regulatory subunit of PDE6, inhibition of catalytic activity
-
phosphate buffer
-
-
-
quercetin-3,5,7,3',4'-O-pentamethylether
-
-
quercetin-3-O-methyl-5,7,3',4'-O-tetraacetate
-
-
quercetin-3-O-methylether
-
-
quinazolinamine
-
IC50: 0.000021 mM, PDE5
rod Pgamma subunit
-
PDE6C is potently inhibited by the recombinant cone and rod Pgamma-subunits with slight selectivity for the cone Pgamma
-
rolipram
RP-73401
-
IC50: 0.0089 mM, PDE5
SCH 51866
0.0029 mM, 50% inhibition of PDE9A5, 0.0033 mM, 50% inhibition of PDE9A1
sciadopitysin
-
IC50: 0.00324 mM
sequoiaflavone
-
IC50: 0.0199 mM
sildenafil
sildenafil citrate
inhibition of PDE5 activity in the intestine, which might occur during sildenafil citrate ingestion, could result in a transitory diarrhoe
SLx-2101
-
inhibits excellent potency both ex vivo and in vivo
sodium deoxycholate
-
-
T-1032
-
IC50: 0.041 mM
T0156
-
selective phosphodiesterase type 5 inhibitor
tadalafil
theophylline
trans-4-([2-[(3-chloro-4-methoxyphenyl)carbamoyl]-4-cyanophenyl]carbamoyl)cyclohexanecarboxylic acid
-
-
udenafil
UK-369,003
-
i.e. 1-[6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridyl sulfonyl]-4-ethylpiperazine benzenesulfonate, a potent selective inhibitor of cGMP-specific PDE5 with more than 80fold selectivity for PDE5 over PDE6, more than 3000fold selectivity over PDEs 1-4 and 10, and more than 10000fold selectivity over PDE11
vardenafil
zaprinast
[4-[(1S,2S)-2-(2H-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]piperazin-1-yl](1H-indol-2-yl)methanone
ZINC44448076
[4-[(1S,2S)-2-(2H-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]piperazin-1-yl](1H-indol-3-yl)methanone
ZINC44448130
additional information
-